http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2380129-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e092ba7c0b4f2beba27b6420c0bd2ce |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2007-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abdb54c692ecda4b6f44a7d871965f92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbf2f2a9247324bbb5c3c15e88a40b9b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f055a93edd0b92e23147019db00d6485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e67b1f8863fd933229aae9c0625ec889 |
| publicationDate | 2012-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2380129-T3 |
| titleOfInvention | A synergistic pharmaceutical combination for cancer treatment |
| abstract | A pharmaceutical combination for use in the treatment of cancer; said combination comprising a cytotoxic antineoplastic agent selected from the group consisting of paclitaxel, docetaxel, doxorubicin and gemcitabine or a pharmaceutically acceptable salt thereof; and a CDK inhibitor or an enantiomer or a pharmaceutically acceptable salt or solvate thereof, wherein said CDK inhibitor is represented by the following formula I; ** Formula ** in which Ar is phenyl, which is unsubstituted or substituted by 1, 2 or 3 identical or different substituents selected from: halogen selected from chlorine, bromine, fluorine or iodine, nitro, cyano, C1-C4- alkyl, trifluoromethyl, hydroxy, C1-C4-alkoxy, carboxy, C1-C4-alkoxycarbonyl, CONH2, and NR1R2; wherein R1 and R2 are selected from hydrogen or C1-C4-alkyl; wherein the use of said combination for the treatment of cancer consists in administering said cytotoxic antineoplastic agent before said CDK inhibitor. |
| priorityDate | 2007-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 160.